Repository logo
 

Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.

Accepted version
Peer-reviewed

Change log

Authors

Jones, Christine L 
Grandi, Vieri 
Amarante, Tauanne D 
Genomics England Research Consortium 

Abstract

T-cell non-Hodgkin's lymphomas develop following transformation of tissue resident T-cells. We performed a meta-analysis of whole exome sequencing data from 403 patients with eight subtypes of T-cell non-Hodgkin's lymphoma to identify mutational signatures and associated recurrent gene mutations. Signature 1, indicative of age-related deamination, was prevalent across all T-cell lymphomas, reflecting the derivation of these malignancies from memory T-cells. Adult T-cell leukemia-lymphoma was specifically associated with signature 17, which was found to correlate with the IRF4 K59R mutation that is exclusive to Adult T-cell leukemia-lymphoma. Signature 7, implicating UV exposure was uniquely identified in cutaneous T-cell lymphoma (CTCL), contributing 52% of the mutational burden in mycosis fungoides and 23% in Sezary syndrome. Importantly this UV signature was observed in CD4 + T-cells isolated from the blood of Sezary syndrome patients suggesting extensive re-circulation of these T-cells through skin and blood. Analysis of non-Hodgkin's T-cell lymphoma cases submitted to the national 100,000 WGS project confirmed that signature 7 was only identified in CTCL strongly implicating UV radiation in the pathogenesis of cutaneous T-cell lymphoma.

Description

Keywords

CD4-Positive T-Lymphocytes, Databases, Genetic, Humans, Interferon Regulatory Factors, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mutation, Sezary Syndrome, Skin Neoplasms, Ultraviolet Rays

Journal Title

Sci Rep

Conference Name

Journal ISSN

2045-2322
2045-2322

Volume Title

11

Publisher

Springer Science and Business Media LLC

Rights

All rights reserved
Sponsorship
Cancer Research UK (23916)
Cancer Research UK (25274)
Cancer Research UK (23433)
Medical Research Council (MC_PC_14089)
Cancer Research UK (C60100/A27815)
CLJ was supported by an educational grant from Galderma. SNZ, AD and TDA are supported by CRUK Pioneer Award (C60100/A23433), CRUK Advanced Clinician Scientist Fellowship (C60100/A23916 and NIHR-BRC Cambridge core grant, and SNZ is supported by Wellcome-Beit Prize, Wellcome Trust Strategic Award (WT100126/B/13/Z) and CRUK PRECISION Grand Challenge award